If deemed to meet the reasonable and necessary criteria, Medicare may – for lecanemab – remove the conditional access barrier it imposed on all beta amyloid-directed monoclonal antibodies in the National Coverage Determination (NCD) issued in April of this year.
Alzheimer’s Drug Lecanemab’s Positive Phase 3 Data Could Lead To Loosening Of Medicare Coverage Restrictions
